Quantitative EEG and apolipoprotein E-genotype improve classification of patients with suspected Alzheimer’s disease

Highlights • Quantitative EEG (qEEG) distinguishes patients with mild cognitive impairment and patients with dementia due to Alzheimer’s disease in the earliest stages of cognitive decline (i.e., MMSE > 23/30 in both groups). • LORETA enables localization of defined areas differentiating between...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Clinical neurophysiology 2013-11, Vol.124 (11), p.2146-2152
Hauptverfasser:	Hatz, F, Benz, N, Hardmeier, M, Zimmermann, R, Rueegg, S, Schindler, C, Miserez, A.R, Gschwandtner, U, Monsch, A.U, Fuhr, P
Format:	Artikel
Sprache:	eng
Schlagworte:	Aged Alzheimer Disease - classification Alzheimer Disease - diagnosis Alzheimer Disease - genetics Alzheimer’s disease Apolipoproteins E - genetics Brain Mapping Cognitive Dysfunction - diagnosis Cognitive Dysfunction - genetics Diagnosis, Differential Electroencephalography Electroencephalography - methods Female Frequency analysis Genotype Humans Logistic Models LORETA Male Mild cognitive impairment Models, Neurological Neurology Surrogate marker Topographic analysis
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Highlights • Quantitative EEG (qEEG) distinguishes patients with mild cognitive impairment and patients with dementia due to Alzheimer’s disease in the earliest stages of cognitive decline (i.e., MMSE > 23/30 in both groups). • LORETA enables localization of defined areas differentiating between disease stages. • qEEG may be a robust and objective marker for disease stage.
ISSN:	1388-2457 1872-8952
DOI:	10.1016/j.clinph.2013.04.339